Identification
- Generic Name
- Sitimagene ceradenovec
- DrugBank Accession Number
- DB04907
- Background
Sitimagene ceradenovec is a novel gene-based product for the treatment of patients with operable high grade glioma, a type of malignant brain tumour, given in addition to standard surgery and radiotherapy/chemotherapy. It is being developed by Ark Therapeutics.
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Gene Therapies
Other gene therapies - Synonyms
- Sitimagene ceradenovec
- External IDs
- EG009
Pharmacology
- Indication
Intended for the treatment of brain cancer.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
EG009 is comprised of a gene encased in a virus vector. Vectors transfer their gene payload into target cells, a process known as transfection, which use this new genetic material as a blueprint for the production of new beneficial proteins. EG009 uses a well-established adenoviral vector (Ad5) to introduce the gene that causes cells to express a protein called thymidine kinase (TK). Following the standard surgery to remove the solid tumour mass, EG009 is injected through the wall of the cavity left behind by the surgical removal of the solid tumour, into the surrounding healthy brain tissue. In the following days, the healthy cells in the wall of the cavity express TK. Five days after surgery, the drug ganciclovir (GCV) is given to the patient as part of the overall EG009 treatment regimen. Neither TK nor GCV is individually active but they react together to produce a substance which destroys cells when they try to divide. Since cell division is a key characteristic of cancer and the normal brain cells are not dividing, cells that try to divide to form a new tumour around the site of the removal of the original tumour are targeted for destruction by the EG009 treatment. EG009 thus works by harnessing healthy cells to produce the substances necessary to destroy newly growing cancer cells.
- Mechanism of action
EG009 works by delivering a gene into the healthy brain cells remaining after the tumour has been removed. These then produce an enzyme that kills the cells trying to divide, preventing a recurrence of a tumour.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAmbroxol The risk or severity of methemoglobinemia can be increased when Sitimagene ceradenovec is combined with Ambroxol. Articaine The risk or severity of methemoglobinemia can be increased when Sitimagene ceradenovec is combined with Articaine. Benzocaine The risk or severity of methemoglobinemia can be increased when Sitimagene ceradenovec is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Sitimagene ceradenovec is combined with Benzyl alcohol. Bupivacaine The risk or severity of methemoglobinemia can be increased when Sitimagene ceradenovec is combined with Bupivacaine. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- International/Other Brands
- Cerepro
Categories
- ATC Codes
- L01XL01 — Sitimagene ceradenovec
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- Not Available
- CAS number
- 898830-54-1
References
- General References
- Not Available
- External Links
- PubChem Substance
- 347909845
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Liquid
- Experimental Properties
- Not Available
Drug created at October 21, 2007 22:23 / Updated at January 14, 2023 19:03